<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28020" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cardiogenic Pulmonary Edema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Muhammad Areeb</given-names>
          </name>
          <aff>Jinnah Hospital/Allama Iqbal Med College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Areeb Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28020.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pulmonary edema is the accumulation of excessive fluid in the alveolar walls and alveolar spaces of the lungs. It can be a life-threatening condition in some patients with high mortality and requires immediate assessment and management. This activity reviews the pathophysiology, clinical presentation, evaluation, and management of cardiogenic pulmonary edema and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology and pathophysiology of cardiogenic pulmonary edema.</p></list-item><list-item><p>Summarize the clinical findings and differential diagnosis of cardiogenic pulmonary edema.</p></list-item><list-item><p>Review the management and complications of cardiogenic pulmonary edema.</p></list-item><list-item><p>Explain the role of the interprofessional team in improving the delivery and outcome of the management provided for better outcomes in patients with cardiogenic pulmonary edema.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28020&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28020">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28020.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Edema refers to excessive fluid accumulation in the interstitial spaces, beneath the skin, or within the body cavities caused by any of the following and producing significant signs and symptoms.<xref ref-type="bibr" rid="article-28020.r1">[1]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>An imbalance among the "Starling forces."&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Damage/blockage of the draining lymphatic system</p>
          </list-item>
        </list>
        <p>The affected body part usually swells if edema is present beneath the skin or produces significant signs and symptoms related to the body cavity involved.</p>
        <p>There are several different types of edema, and a few important ones are peripheral edema, pulmonary edema, cerebral edema, macular edema, and lymphedema. The atypical forms are idiopathic edema and hereditary angioneurotic edema.</p>
        <p>Pulmonary edema refers to the accumulation of excessive fluid in the alveolar walls and alveolar spaces of the lungs. It can be a life-threatening condition in some patients.<xref ref-type="bibr" rid="article-28020.r2">[2]</xref> Pulmonary edema can be:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiogenic (disturbed starling forces involving the pulmonary vasculature and interstitium)</p>
          </list-item>
          <list-item>
            <p>Non-cardiogenic (direct injury/damage to lung parenchyma/vasculature)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28020.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>All the factors that contribute to increased pressure on the left side and the pooling of blood on the left side of the heart can cause cardiogenic pulmonary edema.<xref ref-type="bibr" rid="article-28020.r3">[3]</xref> The result of all these conditions will be increased pressure on the left side of the heart: increased pulmonary venous pressure--&#x0003e; increased capillary pressure in lungs--&#x0003e; pulmonary edema.<xref ref-type="bibr" rid="article-28020.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Coronary artery disease with left ventricular failure (myocardial infarction)</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Valvular heart diseases on the&#x000a0;left<bold>&#x000a0;</bold>side of the heart&#x000a0;(stenosis and regurgitation)</p>
          </list-item>
          <list-item>
            <p>Cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Right to left shunts</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28020.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pulmonary edema is a&#x000a0;life-threatening&#x000a0;condition with an estimated 75000 to 83000 cases per 100000 persons having heart failure and low ejection fraction. A trial showed an alarming 80% prevalence of pulmonary edema in patients with heart failure.<xref ref-type="bibr" rid="article-28020.r5">[5]</xref>&#x000a0;It&#x000a0;is a troublesome condition with the rate of discharge being 74% and the rate of survival after one year of 50%.<xref ref-type="bibr" rid="article-28020.r6">[6]</xref>. The mortality rate at six years follow-up was 85% with patients with congestive heart failure. Males are typically affected more than females, and older patients are at a higher risk for developing pulmonary edema.<xref ref-type="bibr" rid="article-28020.r7">[7]</xref></p>
      </sec>
      <sec id="article-28020.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The cardiogenic form of pulmonary edema (pressure-induced) produces a&#x000a0;non-inflammatory&#x000a0;type of edema by the disturbance in Starling forces. The pulmonary capillary pressure is 10mm Hg (range: 6 to 13) in normal conditions, but any factor that increases this pressure can cause pulmonary edema.<xref ref-type="bibr" rid="article-28020.r8">[8]</xref> The alveoli are normally kept dry because of the negative pressure in extra-alveolar interstitial spaces, but when there is<xref ref-type="bibr" rid="article-28020.r9">[9]</xref>:</p>
        <p>
<bold>Increased pressure/pooling--&#x0003e; Increased pulmonary venous pressure--&#x0003e; Increased pulmonary capillary pressure--&#x0003e; fluid in interstitial spaces--&#x0003e; Increased pressure in interstitial spaces--&#x0003e; fluid in alveoli (pulmonary edema).</bold>
</p>
        <p>Pulmonary capillary wedge pressure can be measured and graded and will produce different presentations on X-rays.</p>
      </sec>
      <sec id="article-28020.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The main features seen on microscopy are<xref ref-type="bibr" rid="article-28020.r10">[10]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alveolar wall thickening</p>
          </list-item>
          <list-item>
            <p>Dilated capillaries and interstitial edema</p>
          </list-item>
          <list-item>
            <p>Transudation in the alveolar lumen (granular and pale eosinophilic)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28020.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually present with shortness of breath, which may be acute in onset (from minutes to hours) or gradual in onset, occurring over hours to days, depending upon the etiology of pulmonary edema.</p>
        <p>Acute pulmonary edema will have<xref ref-type="bibr" rid="article-28020.r11">[11]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Excessive shortness of breath worsening on exertion or lying down</p>
          </list-item>
          <list-item>
            <p>A feeling of the heart sinking and drowning/anxiety worsening on lying down</p>
          </list-item>
          <list-item>
            <p>Gasping for breath</p>
          </list-item>
          <list-item>
            <p>Dizziness and excessive sweating</p>
          </list-item>
          <list-item>
            <p>A cough may be associated with worsening edema</p>
          </list-item>
          <list-item>
            <p>Blood-tinged/pink-colored frothy sputum in very severe disease</p>
          </list-item>
          <list-item>
            <p>Chest pain (myocardial infarction and aortic dissection)</p>
          </list-item>
          <list-item>
            <p>Cold, clammy skin</p>
          </list-item>
        </list>
        <p>Chronic pulmonary edema will have the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Shortness of breath on exertion</p>
          </list-item>
          <list-item>
            <p>Orthopnea</p>
          </list-item>
          <list-item>
            <p>Paroxysmal nocturnal dyspnea</p>
          </list-item>
          <list-item>
            <p>Swelling of the body/lower extremities</p>
          </list-item>
          <list-item>
            <p>Weight gain</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
        </list>
        <p>Ortner syndrome, which refers to hoarseness due to compression of recurrent laryngeal nerve because of an enlarged left atrium, may also be occasionally present in some patients.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>On examination, the positive findings include:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">General appearance</italic>
</p>
          </list-item>
        </list>
        <p>Confusion, agitation, and irritability may be present, associated with excessive sweating, cold extremities, upright posture (sitting upright), and cyanosis of the lips.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">JVP/JVD</italic> &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>Usually raised.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Blood Pressure</italic>
</p>
          </list-item>
        </list>
        <p>Hypertension is more often present, but if hypotension prevails, it is an indicator of severe left ventricular systolic dysfunction, and cardiogenic shock must be ruled out. Cold extremities are a feature of low perfusion and shock.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Respiratory Rate</italic>
</p>
          </list-item>
        </list>
        <p>Tachypnea is usually present, with the patient gasping for breath.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Pulse</italic>
</p>
          </list-item>
        </list>
        <p>Tachycardia (increased heart/ pulse rate) and associated finding of the cause in the pulse.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pedal Edema</p>
          </list-item>
        </list>
        <p>Usually co-exists with pulmonary edema in chronic heart failure.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Respiratory Findings</italic>
</p>
          </list-item>
        </list>
        <p>Dyspnea and tachypnea are usually present and may be associated with the use of accessory muscles for respiration. Fine crackles are usually heard at the bases of the lungs bilaterally and progress apically as the edema worsens. Ronchi and wheezing may also be presenting signs.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Cardiovascular Findings</italic> &#x000a0; &#x000a0; &#x000a0;
<list list-type="bullet"><list-item><p>Tachycardia and hypotension may be present along with jugular venous distention. Auscultation of the heart helps to differentiate between the various causes of valvular lesions causing pulmonary edema.</p></list-item><list-item><p>Auscultation typically reveals an S3 gallop in volume overload states, which may be associated with accentuation of the pulmonic component of S2.</p></list-item><list-item><p>Several different types of murmurs can be heard depending on the cause of the valvular lesion.</p></list-item><list-item><p>Mitral stenosis produces a low-pitched, rumbling diastolic murmur associated with an opening snap at the apex, which becomes accentuated on expiration and produces loud S1.</p></list-item><list-item><p>Mitral regurgitation produces a blowing, high-pitched pan-systolic murmur best heard at the apex, radiating to the left axilla and accentuating on expiration, producing soft S1.</p></list-item><list-item><p>Aortic stenosis produces a harsh crescendo-decrescendo ejection systolic murmur at the aortic area, increasing on expiration, usually radiating towards the&#x000a0;right side of the neck.</p></list-item><list-item><p>Aortic regurgitation produces a high-pitched blowing early diastolic murmur best heard in the aortic area, greatest during expiration.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<italic toggle="yes">Gastrointestinal System</italic>
</p>
          </list-item>
        </list>
        <p>Tender hepatomegaly may be a feature in cases of right-sided cardiac failure, which may worsen to hepatic fibrosis and hepatic cirrhosis in chronic congestion. Ascites may sometimes be present.</p>
      </sec>
      <sec id="article-28020.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>No single definitive test is available for diagnosing pulmonary edema, but clinically, one proceeds from simple to more complex tests while searching for the diagnosis and the associated etiology.</p>
        <p>
<bold>Blood Tests<xref ref-type="bibr" rid="article-28020.r12">[12]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC (to rule out anemia and sepsis)</p>
          </list-item>
          <list-item>
            <p>Serum electrolytes (patients on diuretic therapy may have disturbances )</p>
          </list-item>
          <list-item>
            <p>Pulse oximetry and ABGs (assessing hypoxia and oxygen saturation)</p>
          </list-item>
          <list-item>
            <p>BNP (brain natriuretic peptide levels: low levels rule out cardiogenic type )</p>
          </list-item>
        </list>
        <p><bold>ECG</bold>&#x000a0;</p>
        <p>Used to rule out ischemic changes and rhythm abnormalities.</p>
        <p>
<bold>Radiologic Investigations<xref ref-type="bibr" rid="article-28020.r13">[13]</xref></bold>
</p>
        <p>Chest X-ray (It is one of the most important investigations required for the evaluation of pulmonary edema and overload states.</p>
        <p>
<italic toggle="yes">Early Stage</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In the early stages, cardiomegaly is present, usually identified as an increase of cardiothoracic ratio over 50%.</p>
          </list-item>
          <list-item>
            <p>Broad vascular pedicle</p>
          </list-item>
          <list-item>
            <p>Vascular redistribution</p>
          </list-item>
          <list-item>
            <p>Cephalization</p>
          </list-item>
        </list>
        <p>&#x000a0;<italic toggle="yes">Intermediate Stage</italic></p>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial edema</p>
          </list-item>
          <list-item>
            <p>Kerley B lines</p>
          </list-item>
          <list-item>
            <p>Peribronchial cuffing</p>
          </list-item>
          <list-item>
            <p>Thickened interlobar fissure &#x000a0;&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>&#x000a0;<italic toggle="yes">Late Stage</italic></p>
        <list list-type="bullet">
          <list-item>
            <p>Alveolar edema</p>
          </list-item>
          <list-item>
            <p>Perihilar batwing appearance</p>
          </list-item>
          <list-item>
            <p>Pleural effusion&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Ultrasonography</bold>
</p>
        <p>Ultrasonography may be helpful in further strengthening of diagnosis. Transthoracic ultrasound usually differentiates COPD from CCF as a cause of acute exacerbation of chronic dyspnea.</p>
        <p>
<bold>Echocardiography</bold>
<xref ref-type="bibr" rid="article-28020.r14">[14]</xref>
</p>
        <p>Extremely important in determining the etiology of cardiogenic pulmonary edema. It differentiates systolic from diastolic dysfunction and valvular lesions.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac tamponade</p>
          </list-item>
          <list-item>
            <p>Acute papillary muscle rupture</p>
          </list-item>
          <list-item>
            <p>Acute ventricular septal defect</p>
          </list-item>
          <list-item>
            <p>Valvular lesions</p>
          </list-item>
        </list>
        <p>
<bold>Invasive Technique</bold>
</p>
        <p>
<bold>Pulmonary Arterial Catheter</bold>
</p>
        <p>A Swan-Ganz catheter is inserted into the peripheral vein and advanced until the branch of the pulmonary artery is reached, and then the pulmonary capillary wedge pressure is measured.</p>
      </sec>
      <sec id="article-28020.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>General Management<xref ref-type="bibr" rid="article-28020.r15">[15]</xref></bold>
</p>
        <p>ABC must be addressed initially as the patient arrives.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Airway assessment&#x000a0;</bold>( Make sure the airway is clear for adequate oxygenation and ventilation)</p>
          </list-item>
          <list-item>
            <p><bold>Breathing</bold> ( Note the pattern of breathing and oxygen saturation.)</p>
          </list-item>
          <list-item>
            <p><bold>Circulation</bold> ( Vital signs and cardiac assessment and management )</p>
          </list-item>
          <list-item>
            <p><bold>Oxygen delivery and ventilatory support</bold> (Through nasal cannula, face mask, non-rebreather mask, noninvasive pressure support ventilation, and mechanical ventilation as required)</p>
          </list-item>
          <list-item>
            <p>
<bold>Prop up</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Intravenous access</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Urine output monitoring</bold>
</p>
          </list-item>
        </list>
        <p>After initial airway clearance, oxygenation assessment, and maintenance, management mainly depends upon presentation and should be tailored from patient to patient. Supplemental oxygen is a requirement if the patient is at risk of hypoxemia (SPO2 less than 90% ). Unnecessary oxygen should not be administered as it causes vasoconstriction and reduction in cardiac output. Supplemental oxygen, if necessary, should be given in the following order:</p>
        <p>
<bold>Nasal cannula and face mask ---&#x0003e; Non-rebreather mask ---&#x0003e; Trial of non-invasive ventilation (NIV) ---&#x0003e; Intubation and mechanical ventilation</bold>
</p>
        <p>If the respiratory distress and hypoxemia continue on oxygen supplementation, a trial of non-invasive ventilation should follow if there are no contraindications of NIV, as evidence suggests that it lowers the need for intubation and improves respiratory parameters. If the patient does not improve or has contraindications to NIV, then intubation and mechanical ventilation&#x000a0;(with high positive end-expiratory pressure) should be considered.</p>
        <p>
<bold>Specific Management<xref ref-type="bibr" rid="article-28020.r16">[16]</xref><xref ref-type="bibr" rid="article-28020.r17">[17]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Treatment of the underlying cause.</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Non Invasive Management</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Invasive Management</bold>
</p>
          </list-item>
        </list>
        <p><bold>Non-Invasive Management<xref ref-type="bibr" rid="article-28020.r18">[18]</xref>&#x000a0;</bold>can be achieved by:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Pre-Load Reduction which can be achieved by:</bold>
</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Nitroglycerin</p>
          </list-item>
          <list-item>
            <p>Sodium nitroprusside</p>
          </list-item>
          <list-item>
            <p>Isosorbide dinitrate</p>
          </list-item>
          <list-item>
            <p>Loop diuretics (furosemide, torsemide, bumetanide)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Morphine and nesiritide require extreme care.</p>
          </list-item>
          <list-item>
            <p>BIPAP can help move the fluid out of the lungs by increasing the intrapulmonary pressure</p>
          </list-item>
        </list>
        <p>After initial resuscitation and management, the mainstay of treatment in acute settings is diuresis with or without vasodilatory therapy. The aggressiveness of treatment depends upon the initial presentation, hemodynamic, and volume status of the patient. VTE prophylaxis is generally indicated in patients admitted with acute heart failure. Sodium restriction is also necessary for patients with HF.</p>
        <p>Patients presenting with acute decompensated heart failure (ADHF) with features of pulmonary edema should be treated with intravenous diuretics initially, regardless of the etiology. Patients with HF and features of pulmonary edema receiving treatment with early administration of diuretics had better outcomes according to guidelines of the American College of Cardiology Foundation/ American Heart Association Task Force.<xref ref-type="bibr" rid="article-28020.r19">[19]</xref>&#x000a0;A prospective observational study suggested that early treatment with furosemide in patients with AHF lowers in-hospital mortality, and the mortality increases with a delay in the time of administration.<xref ref-type="bibr" rid="article-28020.r20">[20]</xref>&#x000a0;Diuretic therapy for patients who have not received diuretics previously is as follows:</p>
        <p>If renal function is adequate: &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Furosemide: 20 to 40 mg IV&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Torsemide: 10 to 20 mg IV&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bumetanide: 1 mg IV</p>
          </list-item>
        </list>
        <p>If renal function is deranged/severe HF:</p>
        <list list-type="bullet">
          <list-item>
            <p>Furosemide: up to 160 to 200 mg IV bolus, or can be given as 5 to 10mg/hr drip.</p>
          </list-item>
          <list-item>
            <p>Torsemide: up to 100 to 200 mg IV bolus</p>
          </list-item>
          <list-item>
            <p>Bumetanide: 4 to 8 mg IV bolus</p>
          </list-item>
        </list>
        <p>If the patient shows normal renal function, and there is very little/no response to initial treatment, the dose of diuretics should be doubled at 2-hour intervals until achieving the maximum recommended.</p>
        <p>The patients who are on chronic diuretic therapy should receive higher doses of diuretics in acute settings. The initial dose for such patients should be greater than two times of daily maintenance dose. A continuous infusion can also be used as an alternative to bolus therapy if the patient responds to the bolus dose.&#x000a0;</p>
        <p>While being managed in the hospital for pulmonary edema, IV diuresis can be used using loop diuretics. Furosemide is the usual drug of choice. While diuresis, one should monitor the following:</p>
        <list list-type="order">
          <list-item>
            <p>Daily weight</p>
          </list-item>
          <list-item>
            <p>Strict intake and output measures</p>
          </list-item>
          <list-item>
            <p>Telemetry</p>
          </list-item>
          <list-item>
            <p>A basic metabolic panel including kidney functions and electrolytes</p>
          </list-item>
          <list-item>
            <p>Keep serum potassium above 4.0 mEq/L and Mg over 2.0 mEq/L.</p>
          </list-item>
          <list-item>
            <p>Continuous pulse ox if indicated&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Renal functions&#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>In addition to diuretic therapy, vasodilator therapy may be necessary. Indications include:</p>
        <list list-type="order">
          <list-item>
            <p>Urgent afterload reduction ( severe hypertension )</p>
          </list-item>
          <list-item>
            <p>Adjunct to diuretics when the patient doesn't respond to diuretic therapy alone</p>
          </list-item>
          <list-item>
            <p>For patients with refractory heart failure and decreased cardiac output</p>
          </list-item>
        </list>
        <p>Vasodilator therapy has to be used with great caution since it can cause symptomatic hypotension, and the evidence of its efficacy and safety is very limited. When they are needed, they should be used with great caution while monitoring hemodynamic response under expert opinion.</p>
        <p>Nitrates (nitroglycerin and isosorbide dinitrate) cause greater venodilation than arterio-dilation and can be used intravenously in recommended doses. Nitroglycerin can be used at 5 to 10 mcg/min initially and can be increased gradually to the maximum recommended dose (200 mcg/min) while closely monitoring the hemodynamic responses. Isosorbide dinitrate has a much longer half-life than nitroglycerin, which puts it at a disadvantage if the drug requires discontinuation because of symptomatic hypotension.</p>
        <p>Sodium nitroprusside causes both venous and arterio-dilation and can significantly lower blood pressure. It requires close hemodynamic monitoring through an intra-arterial catheter. It is used initially in a dose of 5 to 10 mcg/min, which can be titrated up to 400 mcg/min, which is the maximum recommended dose. At higher doses, it increases the risk of cyanide toxicity. Hence, it has to be used with extreme caution and with close monitoring under expert supervision.</p>
        <p>Nesiritide should not routinely be a therapeutic option for the treatment of HF. A large randomized trial fusing nesiritide in patients of acutely decompensated heart failure (ADHF)&#x000a0; shows that it was not associated with any change in the rate of death or rehospitalization, increased risk of hypotension, and a small non-significant change in dyspnea.<xref ref-type="bibr" rid="article-28020.r21">[21]</xref>&#x000a0; Nesiritide, if used, should be used initially as an intravenous bolus of 2 mcg/kg and afterward a continuous infusion of 0.01 mcg/kg.</p>
        <p>Salt and water restriction is generally indicated for patients with HF.</p>
        <p>Vasopressor receptor antagonist (tolvaptan) can also be used with caution and under supervision.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>After-Load Reduction which can be achieved by:</bold>
</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI):&#x000a0; captopril, enalapril, lisinopril, perindopril, etc.</p>
          </list-item>
          <list-item>
            <p>ARBs (angiotensin receptor blockers): valsartan, telmisartan, olmesartan, candesartan, etc.</p>
          </list-item>
          <list-item>
            <p>Sodium nitroprusside</p>
          </list-item>
        </list>
        <p>ACE inhibitors, or ARNI, are the mainstay of chronic treatment for patients with HFrEF. If the patient doesn't tolerate ACE inhibitors or ARNI, then ARB should be considered the first-line choice for prolonged treatment. Beta-blockers and mineralocorticoid receptor antagonists require extra care if used.&#x000a0;</p>
        <p>If blood pressure is low, start ionotropic agents, and vasopressors (catecholamines and phosphodiesterase inhibitors) should commence. The treatment for heart failure with reduced ejection fraction (HFrEF) differs from heart failure with preserved ejection fraction. (HFpEF).</p>
        <p>For patients of HFrEF presenting with hypotension, intense hemodynamic monitoring is necessary. The patient should undergo evaluation for signs of shock (confusion, cold extremities, decreased urine output, etc.). If the patient of HFrEF has signs of hypotension and/or blood pressure less than 80mmg, Ionotropes should be added immediately and titrated accordingly. For patients with persistent shock, vasopressors also have to be added.&#x000a0;</p>
        <p>For patients with HFpEF, only vasopressors are necessary. Inotropes are NOT indicated in patients with HFpEF and dynamic left ventricular obstruction (most commonly hypertrophic obstructive cardiomyopathy).&#x000a0;</p>
        <p>
<bold>Invasive Management<xref ref-type="bibr" rid="article-28020.r14">[14]</xref></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>IABP </bold>(intra-aortic balloon pump)</p>
          </list-item>
          <list-item>
            <p>
<bold>Ultrafiltration</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Ventricular assist devices</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>ECMO (extracorporeal membrane oxygenation)&#x000a0;</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>Cardiac transplant</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Valve replacement</bold><bold>&#x000a0;</bold>(in case of valvular issues)</p>
          </list-item>
          <list-item>
            <p>
<bold>PCI (percutaneous coronary intervention)</bold>
</p>
          </list-item>
          <list-item>
            <p>
<bold>CABG (coronary artery bypass graft)</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Intubation </bold>(if required to maintain the airway and also helps in moving the fluid out)</p>
          </list-item>
        </list>
        <p>In a patient of severe HFrEF with acute hemodynamic compromise and cardiogenic shock, mechanical cardiac support is available while waiting on a decision or waiting on recovery, hence called " bridge to the decision and "bridge to recovery." The patients usually have blood pressure less than 90mmHg, PCWP greater than 18mmHg, and a cardiac index of less than 2L/min per meter square.&#x000a0;</p>
        <p><bold>IABP (intra-aortic balloon pump) is the device that is used most commonly among mechanical circulatory devices as it is the least expensive, easily insertable, and readily available.</bold> It consists of a balloon in the aorta that inflates and deflates synchronously with the heartbeat, causing increased cardiac output and coronary flow. IABPs are commonly used for temporary circulatory support with patients with advanced heart failure while waiting for a heart transplant or VADs. It is not a definitive therapy but is widely used as a bridge therapy for patients with cardiogenic shock and also as an adjunct to thrombolysis in acute myocardial infarction for stabilization.</p>
        <p><bold>Ventricular assist devices, as compared to IABP, have greater efficacy in increasing the hemodynamic parameters.</bold> These have more complications and require more expertise, take longer to insert and cost more in comparison. They are an option in acute decompensated heart failure. They can also be useful in complications of acute heart failure like cardiogenic shock, mitral regurgitation, and VSDs. They can be different kinds, like the left ventricle to the aorta, the left atrium to the aorta, the right ventricular assist device, etc.&#x000a0;</p>
        <p><bold>Ultrafiltration</bold> (UF) is the most effective approach for sodium, and water removal effectively improves hemodynamics in patients with heart failure. UF is the process of abstracting plasma water from the whole blood across a hemofilter because of the transmembrane pressure gradient. It is preferred over diuretics because it removes sodium and water more effectively and does not stimulate neurohormonal activation through macula densa. UF is used in patients with HF as it decreases PCWP, restores diuresis, reduces diuretic requirements, corrects hyponatremia, improves cardiac output, and thus improves congestion.<xref ref-type="bibr" rid="article-28020.r22">[22]</xref>&#x000a0; In some patients with heart failure, UF was associated with improved cardiac index and oxygenation capacity, decreased PCWP, and less need for inotropes.<xref ref-type="bibr" rid="article-28020.r23">[23]</xref>&#x000a0;Several types of UF are isolated, intermittent, and continuous. The continuous type can work in an arterio-venous or veno-venous mode, which is the most common type.</p>
        <p>UF can be crucial in patients with heart failure and resistance to diuretic therapy and can serve to optimize the volume status. Many questions regarding UF require examination in further studies, and the evidence does not support its widespread use as a substitute for diuretics.<xref ref-type="bibr" rid="article-28020.r24">[24]</xref></p>
      </sec>
      <sec id="article-28020.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential Diagnosis includes<xref ref-type="bibr" rid="article-28020.r25">[25]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory failure</p>
          </list-item>
          <list-item>
            <p>Myocardial ischemia/infarct</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Neurogenic pulmonary edema</p>
          </list-item>
          <list-item>
            <p>High-altitude pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Acute respiratory distress syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28020.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis mainly depends on the underlying cause but generally has a poor prognosis. Cardiogenic pulmonary edema is an alarming condition with the rate of discharge being 74% and the rate of survival after one year of 50%.<xref ref-type="bibr" rid="article-28020.r6">[6]</xref>&#x000a0;The mortality rate at 6 years follow-up is 85% with patients of congestive heart failure.<xref ref-type="bibr" rid="article-28020.r7">[7]</xref></p>
      </sec>
      <sec id="article-28020.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Most complications of pulmonary edema arise from the complications of the underlying cause. Common complications associated with cardiogenic etiologies include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Risk of arrhythmias (atrial fibrillation, ventricular fibrillation, ventricular tachycardias)</p>
          </list-item>
          <list-item>
            <p>Thromboembolism (pulmonary embolism, DVT, stroke)</p>
          </list-item>
          <list-item>
            <p>Pericarditis</p>
          </list-item>
          <list-item>
            <p>Rupture</p>
          </list-item>
          <list-item>
            <p>Valvular heart disease</p>
          </list-item>
          <list-item>
            <p>Cardiogenic shock</p>
          </list-item>
          <list-item>
            <p>Tamponade</p>
          </list-item>
          <list-item>
            <p>Dressler syndrome</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
        <p>Pulmonary edema can cause severe hypoxia and hypoxemia, leading to end-organ damage and multi-organ failure. Respiratory failure is another common complication of cardiogenic pulmonary edema.</p>
      </sec>
      <sec id="article-28020.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>As cardiac events are the prime factors for the development of pulmonary edema, patients are advised to control and prevent the progression of heart disease by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Healthy lifestyle and exercise</p>
          </list-item>
          <list-item>
            <p>Smoking cessation</p>
          </list-item>
          <list-item>
            <p>Alcohol cessation</p>
          </list-item>
          <list-item>
            <p>Weight reduction and monitoring</p>
          </list-item>
          <list-item>
            <p>Proper diet control</p>
          </list-item>
          <list-item>
            <p>Low cholesterol diet</p>
          </list-item>
          <list-item>
            <p>Reducing salt intake</p>
          </list-item>
          <list-item>
            <p>Blood pressure control</p>
          </list-item>
          <list-item>
            <p>Good glycemic control</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28020.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pulmonary edema can be a very life-threatening condition, and specialized consultation is a requirement for diagnosis and management. Considering a very high short-term mortality rate, an Interprofessional team approach is recommended in the management of these patients to improve outcomes.</p>
        <p>Starting from the diagnosis, etiological factor, and management of the patient, a well-coordinated team needs to work for better patient care involving all the related departments. All the available treatment options need to be discussed to avoid any complications and improve the outcome. The use of non-invasive positive pressure ventilation has a significant benefit in acute cardiogenic pulmonary edema.<xref ref-type="bibr" rid="article-28020.r26">[26]</xref> [Level-2]</p>
        <p>While the physician is involved primarily in the management of the patient, consultation is also necessary from a team of specialists involving cardiologists, pulmonologists, and cardiothoracic surgeons. The nurses are also vital members of the interprofessional group, as they will monitor the patient's vital signs and communicate back to the team with results. The nurse practitioner, like the primary care provider, follows these patients in an outpatient setting and should try and reduce the risk factors for ischemic heart disease. Patients should be urged to quit smoking, enroll in cardiac rehabilitation, maintain a healthy body weight, become physically active, and remain compliant with follow-up appointments and medications. A dietary consult should be obtained to educate the patient on a healthy diet and what foods to avoid.</p>
        <p>Since most patients with heart failure are no longer able to work, social work assistance is crucial so that the patient can get the much-needed medical support.</p>
        <p>The role of pharmacists will be to ensure that the patient is on the right medication and dosage. The radiologist can also play a vital role in determining the cause of dyspnea. A mental health nurse should consult with the patient because depression and anxiety are common morbidities, leading to poor quality of life.</p>
        <p>As shown above, cardiogenic pulmonary edema requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, other ancillary therapists (respiratory, social worker), and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]</p>
        <p>If the patient is deemed to be a candidate for a ventricular assist device or heart transplant, the transplant nurse should be involved early in the care. With a shortage of organs, one also has to be realistic with patients.</p>
        <p>At the moment, the&#x000a0;role of morphine and nesiritide remains questionable and requires further evaluation.<xref ref-type="bibr" rid="article-28020.r27">[27]</xref><xref ref-type="bibr" rid="article-28020.r28">[28]</xref></p>
        <p>Outcomes</p>
        <p>Unfortunately, despite optimal treatment, the outcomes for cardiogenic pulmonary edema/heart failure are abysmal. There is no cure for this disorder, and the key is to prevent the condition in the first place.</p>
      </sec>
      <sec id="article-28020.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28020&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28020">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/cardiogenic-pulmonary-edema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28020">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28020/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28020">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28020.s16">
        <fig id="article-28020.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Kerley lines in Congestive heart failure Image courtesy of S bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kerley" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28020.s17">
        <title>References</title>
        <ref id="article-28020.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trayes</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Studdiford</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Pickle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tully</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Edema: diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Jul</month>
            <day>15</day>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-10</page-range>
            <pub-id pub-id-type="pmid">23939641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Punton</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute pulmonary oedema.</article-title>
            <source>Nurs Stand</source>
            <year>2016</year>
            <month>Feb</month>
            <day>03</day>
            <volume>30</volume>
            <issue>23</issue>
            <fpage>51</fpage>
            <page-range>51-9; quiz 60</page-range>
            <pub-id pub-id-type="pmid">26838657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sureka</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary edema - cardiogenic or noncardiogenic?</article-title>
            <source>J Family Med Prim Care</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>290</fpage>
            <pub-id pub-id-type="pmid">25949989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alwi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of cardiogenic pulmonary edema.</article-title>
            <source>Acta Med Indones</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>176</fpage>
            <page-range>176-84</page-range>
            <pub-id pub-id-type="pmid">20973297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Platz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>906</fpage>
            <page-range>906-16</page-range>
            <pub-id pub-id-type="pmid">26230356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crane</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, treatment and outcome of acidotic, acute, cardiogenic pulmonary oedema presenting to an emergency department.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>320</fpage>
            <page-range>320-4</page-range>
            <pub-id pub-id-type="pmid">12501030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiener</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Richeson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gatewood</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Hospital and long-term survival of patients with acute pulmonary edema associated with coronary artery disease.</article-title>
            <source>Am J Cardiol</source>
            <year>1987</year>
            <month>Jul</month>
            <day>01</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-5</page-range>
            <pub-id pub-id-type="pmid">3604942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary edema: pathophysiology and diagnosis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-60, i</page-range>
            <pub-id pub-id-type="pmid">21219673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibbald</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Holliday</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of pulmonary edema associated with the adult respiratory distress syndrome.</article-title>
            <source>Can Med Assoc J</source>
            <year>1979</year>
            <month>Feb</month>
            <day>17</day>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-50</page-range>
            <pub-id pub-id-type="pmid">376080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miles</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary edema: an anatomic, pathophysiologic, and roentgenologic analysis.</article-title>
            <source>J Natl Med Assoc</source>
            <year>1977</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-82</page-range>
            <pub-id pub-id-type="pmid">875070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guntupalli</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Acute pulmonary edema.</article-title>
            <source>Cardiol Clin</source>
            <year>1984</year>
            <month>May</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-200</page-range>
            <pub-id pub-id-type="pmid">6443344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Modern management of cardiogenic pulmonary edema.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>1105</fpage>
            <page-range>1105-25</page-range>
            <pub-id pub-id-type="pmid">16199340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ootaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Radiographic diagnosis of cardiogenic pulmonary edema].</article-title>
            <source>Nihon Igaku Hoshasen Gakkai Zasshi</source>
            <year>1999</year>
            <month>May</month>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>223</fpage>
            <page-range>223-30</page-range>
            <pub-id pub-id-type="pmid">10388306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Acute Pulmonary Edema.</article-title>
            <source>Curr Treat Options Cardiovasc Med</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>269</fpage>
            <page-range>269-276</page-range>
            <pub-id pub-id-type="pmid">11096492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez Marteles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urrutia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Acute heart failure: acute cardiogenic pulmonary edema and cardiogenic shock].</article-title>
            <source>Med Clin (Barc)</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>142 Suppl 1</volume>
            <fpage>14</fpage>
            <page-range>14-9</page-range>
            <pub-id pub-id-type="pmid">24930078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baird</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute pulmonary oedema - management in general practice.</article-title>
            <source>Aust Fam Physician</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>910</fpage>
            <page-range>910-4</page-range>
            <pub-id pub-id-type="pmid">21301670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chioncel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ambrosy</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Gheorghiade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Oedema-Therapeutic Targets.</article-title>
            <source>Card Fail Rev</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-45</page-range>
            <pub-id pub-id-type="pmid">28785430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Management of acute cardiogenic pulmonary edema: a literature review.</article-title>
            <source>Adv Emerg Nurs J</source>
            <year>2009</year>
            <season>Jan-Mar</season>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-43</page-range>
            <pub-id pub-id-type="pmid">20118852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>WRITING COMMITTEE MEMBERS</collab>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>e240</fpage>
            <page-range>e240-327</page-range>
            <pub-id pub-id-type="pmid">23741058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Damman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Voors</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kagiyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oishi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inuzuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Matsukawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naruke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mizutani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kitai</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>27</day>
            <volume>69</volume>
            <issue>25</issue>
            <fpage>3042</fpage>
            <page-range>3042-3051</page-range>
            <pub-id pub-id-type="pmid">28641794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hasselblad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Heizer</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Komajda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massie</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nieminen</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Reist</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Battler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Botero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bohidar</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clausell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corbal&#x000e1;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Costanzo</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dahlstrom</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Deckelbaum</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Felker</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gennevois</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Howlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kociol</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laucevicius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tanomsup</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teerlink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Triposkiadis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Troughton</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Voors</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Whellan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Effect of nesiritide in patients with acute decompensated heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jul</month>
            <day>07</day>
            <volume>365</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-43</page-range>
            <pub-id pub-id-type="pmid">21732835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marenzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grazi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giraldi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perego</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salvioni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guazzi</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration.</article-title>
            <source>Am J Med</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>94</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-56</page-range>
            <pub-id pub-id-type="pmid">8420299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coraim</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Wolner</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Continuous hemofiltration for the failing heart.</article-title>
            <source>New Horiz</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>725</fpage>
            <page-range>725-31</page-range>
            <pub-id pub-id-type="pmid">8574603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiaccadori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Regolisti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maggiore</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Parenti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cremaschi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Detrenis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caiazza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cabassi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ultrafiltration in heart failure.</article-title>
            <source>Am Heart J</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>161</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <page-range>439-49</page-range>
            <pub-id pub-id-type="pmid">21392597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akaba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kadota</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema.</article-title>
            <source>Crit Care</source>
            <year>2017</year>
            <month>Aug</month>
            <day>25</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>228</fpage>
            <pub-id pub-id-type="pmid">28841896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potts</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Noninvasive positive pressure ventilation: effect on mortality in acute cardiogenic pulmonary edema: a pragmatic meta-analysis.</article-title>
            <source>Pol Arch Med Wewn</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>119</volume>
            <issue>6</issue>
            <fpage>349</fpage>
            <page-range>349-53</page-range>
            <pub-id pub-id-type="pmid">19694215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellingsrud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Morphine in the treatment of acute pulmonary oedema--Why?</article-title>
            <source>Int J Cardiol</source>
            <year>2016</year>
            <month>Jan</month>
            <day>01</day>
            <volume>202</volume>
            <fpage>870</fpage>
            <page-range>870-3</page-range>
            <pub-id pub-id-type="pmid">26476045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28020.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howlett</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Current treatment options for early management in acute decompensated heart failure.</article-title>
            <source>Can J Cardiol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>24 Suppl B</volume>
            <issue>Suppl B</issue>
            <fpage>9B</fpage>
            <page-range>9B-14B</page-range>
            <pub-id pub-id-type="pmid">18629382</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
